SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : BDX--Becton Dickinson: finished off or opportunity knocks?

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kendall harmon who wrote ()6/14/1999 6:37:00 PM
From: kendall harmon  Read Replies (1) of 11
 
From white 06897 on the Yahoo thread:

To: buysellbuysell

Two reasons substantiate any value to the theory that ABT may takeover BDX:

1) ABT chief executive officer stated to the press that ABT would consider acquiring companies with a market capitalization of ten to fifteen billion dollars... only a few pharmaceutical and medical device companies fit that range, and BDX is one of them.

2) At or around the time of the announcemnt as described above, there was very unusual BDX call option activity. Call options were so active as to make headlines. I don't know the specifics, but something like a year's worth of call contract volume took place in a few weeks. Now remember, this was a while back.

These are facts. I do not hype, and do not appreciate hype. I do not pretend to know any more than I do, though I have been accused of hype on this board.

In my honest opinion, BDX is a quality company at a reasonable price. I am heavily invested, and have been since 1992. The worst scenario: you own a quality company at a reasonable price. The best scenario: you wake up one Monday morning and hear the news ABT is acquiring BDX at a hefty premium.

Best of luck. <i/>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext